Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

This study evaluates whether a highly sensitive blood test called digital PCR can detect tiny amounts of remaining cancer cells (called MRD — measurable residual disease) after a bone marrow or stem cell transplant for blood cancers. Catching residual disease early could allow doctors to act before a full relapse occurs. **You may be eligible if...** - You have had a stem cell or bone marrow transplant for a blood cancer - Your cancer had a known fusion gene or mutation at diagnosis that can be tracked with digital PCR - You have achieved engraftment (the transplant has taken hold) and have had at least one MRD test by digital PCR after the transplant **You may NOT be eligible if...** - You relapsed or died before your first digital PCR test after transplant - Your cancer did not have detectable genetic markers at diagnosis - You only underwent conventional PCR testing without the digital method Talk to your doctor to see if this trial is right for you.